RhumbLine Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $748K | Sell |
|
|||||
|
2025
Q2 | $507K | Buy |
|
|||||
|
2025
Q1 | $477K | Buy |
|
|||||
|
2024
Q4 | $423K | Buy |
|
|||||
|
2024
Q3 | $383K | Sell |
|
|||||
|
2024
Q2 | $205K | Buy |
|
|||||
|
2024
Q1 | $352K | Buy |
|
|||||
|
2023
Q4 | $333K | Buy |
|
|||||
|
2023
Q3 | $247K | Buy |
|
|||||
|
2023
Q2 | $294K | Buy |
|
|||||
|
2023
Q1 | $296K | Buy |
|
|||||
|
2022
Q4 | $327K | Buy |
|
|||||
|
2022
Q3 | $251K | Buy |
|
|||||
|
2022
Q2 | $215K | Buy |
|
|||||
|
2022
Q1 | $548K | Buy |
|
|||||
|
2021
Q4 | $483K | Sell |
|
|||||
|
2021
Q3 | $674K | Buy |
|
|||||
|
2021
Q2 | $788K | Sell |
|
|||||
|
2021
Q1 | $675K | Sell |
|
|||||
|
2020
Q4 | $737K | Buy |
|
|||||
|
2020
Q3 | $476K | Sell |
|
|||||
|
2020
Q2 | $414K | Sell |
|
|||||
|
2020
Q1 | $360K | Sell |
|
|||||
|
2019
Q4 | $499K | Buy |
|
|||||
|
2019
Q3 | $428K | Buy |
|
|||||
|
2019
Q2 | $596K | Buy |
|
|||||
|
2019
Q1 | $548K | Sell |
|
|||||
|
2018
Q4 | $502K | Buy |
|
|||||
|
2018
Q3 | $471K | Sell |
|
|||||
|
2018
Q2 | $440K | Buy |
|
|||||
|
2018
Q1 | $474K | Buy |
|
|||||
|
2017
Q4 | $459K | Sell |
|
|||||
|
2017
Q3 | $360K | Buy |
|
|||||
|
2017
Q2 | $382K | Buy |
|
|||||
|
2017
Q1 | $437K | Buy |
|
|||||
|
2016
Q4 | $260K | Sell |
|
|||||
|
2016
Q3 | $451K | Sell |
|
|||||
|
2016
Q2 | $276K | Buy |
|
|||||
|
2016
Q1 | $221K | Buy |
|
|||||
|
2015
Q4 | $310K | Buy |
|
|||||
|
2015
Q3 | $235K | Buy |
|
|||||
|
2015
Q2 | $294K | Sell |
|
|||||
|
2015
Q1 | $471K | Buy |
|
|||||
|
2014
Q4 | $284K | Buy |
|
|||||
|
2014
Q3 | $223K | Hold |
|
|||||
|
2014
Q2 | $417K | Sell |
|
|||||
|
2014
Q1 | $452K | Sell |
|
|||||
|
2013
Q4 | $343K | Sell |
|
|||||
|
2013
Q3 | $458K | Sell |
|
|||||
|
2013
Q2 | $430K | Buy |
|